Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

ABSTRACT: The advent of next generation sequencing (NGS) technologies has advanced our understanding of the intrinsic biology of different gastrointestinal (GI) tumor types. The use of novel, more efficient sequencing platforms has improved turnaround times of sequencing results. This is providing real time opportunities to put precision medicine to the test. A number of early phase clinical trials are testing targeted therapies in unique molecularly characterized subsets of patients (baskets). While basket studies are gaining momentum, treatment failures serve to remind us that shifting from a histology-driven to a histology-agnostic approach is unlikely to be a failure-free strategy for a number of tumor types as recently learnt from vemurafenib failure in BRAF mutated metastatic colorectal

SUBMITTER: Au TH 

PROVIDER: S-EPMC5506274 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature